Synlogic, a Cambridge, Mass.-based biopharmaceutical company developing novel therapies based on synthetic biology and the microbiome called “synthetic biotics”, raised a new funding.
It added to the previously announced Series A financing round which totals approximately $30m.
The company also appointed Bharatt Chowrira, Ph.D., J.D., as president to expand its business opportunities and pipeline around its proprietary synthetic biotic platform, including advancement of its two lead rare disease therapeutic programs toward clinical studies and the signing of a multi-year R&D collaboration focused on inflammatory bowel disease (IBD) with an undisclosed global pharmaceutical company. In his role as president of Synlogic, Dr. Chowrira will oversee the company’s corporate and business development, alliance management, financial and legal operations, and he will report to Jose-Carlos (JC) Gutiérrez-Ramos, Ph.D., the Chief Executive Officer.
Led by Dr. Gutiérrez-Ramos, CEO, Synlogic is initially focused on developing synthetic biotic therapies for the treatment of inborn errors of metabolism (IEM). The company’s two lead programs are being advanced for the potential treatment of rare metabolic disorders of Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
The proceeds from the accelerated Series A funding to advance these programs into the clinic.
Founded in 2014, Synlogic is backed by Atlas Venture, New Enterprise Associates (NEA) and the Bill & Melinda Gates Foundation.
FinSMEs
17/09/2015